Receptors used by natural killer (NK) cells to mediate natural cytotoxicity are poorly defined, although it is now clear that a number of adhesion molecules can serve this function. CD38 transduces signals on T- and B-cell lines, and we asked whether it could trigger lytic and secretory responses in human NK cells. By using an anti-CD38 monoclonal antibody in reverse antibody-dependent cellular cytotoxicity experiments, it is shown that CD38 engagement triggers cytotoxic responses by activated NK cells, but not by cytotoxic T lymphocytes or fresh NK cells. Cross-linking with anti-CD38 F(ab′)2 caused activated NK cells to release granzymes and cytokines, but did not trigger an increase in intracellular Ca2+. Fresh NK cells acquired CD38-dependent lytic function during activation with interleukin-2 (IL-2), and inhibitor studies suggested that IL-2 stimulated the de novo expression of proteins that act between CD38 and the lytic machinery in NK cells. The induction of proteins that link commonly expressed adhesion molecules to effector mechanisms could provide a paradigm for pathogen recognition by the innate immune system.

NATURAL KILLER (NK) CELLS, the primary lymphoid mediators of natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC), are controlled by positive and negative cytolytic signals.1,2 Negative signals are transduced by 2 classes of major histocompatibility complex (MHC) I-binding molecules: by receptors containing Ig-like domains known as KIRs in humans and receptors, including the Ly-49 family of proteins in mice and CD94/NKG2A in humans that have extracellular C-lectin domains,3,4 and by molecules with unknown specificity.5 The best-characterized positive triggering molecule on NK cells is CD16 (FcγRIIIA), the receptor responsible for mediating ADCC.1,6 CD16 associates noncovalently with γ and ζ homodimers and heterodimers that contain tyrosine-based activation motifs (ITAMs) in their cytoplasmic domains. Cross-linking of CD16 leads to phosphorylation of these ITAMs and ofsyk, ZAP-70, and phospholipase C-γ (PLC-γ), followed by a number of downstream events, including the release of intracellular Ca2+, that ultimately result in the exocytosis of cytolytic granules at the effector-target interface. It has been recently shown that activating forms of KIRs and Ly-49 follow a similar positive signaling pathway but use DAP-12, a homologue of ζ, as a signal transducer.3,7 8 

Receptors mediating natural cytotoxicity, the innate ability of NK cells to lyse tumor or virally infected target cells in the absence of antibody, have been more difficult to characterize because multiple different receptors can trigger cytolysis. Thus, a monoclonal antibody (MoAb) to any 1 triggering molecule would only marginally inhibit lysis. However, it has been possible to bypass the normal receptor-ligand interaction and to study the capacity of individual molecules to transduce cytotoxic signals by using receptor-specific IgG MoAbs to redirect lysis of FcγR+ target cells.9,10 By using this approach, a number of cytotoxic triggering molecules have been identified, including CD2,11-13 CD44,14-16 CD69,17NKRP-1,18 CD40,19 B7.2,19 and NK-TR,20 suggesting that these molecules might be involved in natural cytotoxicity. Another molecule expressed by NK cells is CD38, a type II integral membrane receptor that binds to CD31 (PECAM-1) and has adenosine diphosphate (ADP)-ribosyl cyclase ectoenzymatic activity.21-23 CD38 is expressed early in the differentiation of CD34+ stem cells to lymphocytes and remains in mature, CD56+, CD16+ NK cells24,25 but not in resting B or T cells, although it is re-expressed in activated T cells. Ligation of CD38 on Jurkat T cells,26,27 immature B cells,28 and differentiated HL-60 cells29 by anti-CD38 MoAbs induces protein tyrosine phosphorylation. In Jurkat, but not in immature B cells or MHC-nonrestricted T cells,30 CD38 cross-linking also induces increases in intracellular Ca2+. A number of important functional consequences of CD38 engagement include upregulation of receptors such as B7.231 and CD73,32 apoptosis,27proliferation,31 and cytokine release.30 

The potent signaling properties of CD38 in T-cell, B-cell, and granulocytic cell lines prompted us to ask whether CD38 might also serve as a cytotoxic triggering molecule on NK cells. We show here that an agonistic anti-CD38 MoAb redirects cell-mediated cytolysis and induces cytokine and granzyme release in activated NK cells. We conclude that the CD38 adhesion molecule is indeed a cytotoxic trigger on NK cells that could contribute significantly to the positive triggering events leading to natural cytotoxicity.

Antibodies and reagents.

Phycoerythrin (PE)-anti-CD38 (H1T2), PE-anti-CD16 (3G8), and unconjugated anti-CD11a (G43-25B, IgG2b and HI111, IgG1) and anti-CD56 (B159, IgG1) were from Pharmingen (San Diego, CA). 3G8 (IgG1, anti-CD1633), OKT3 (IgG2a anti-CD334), W6/32 (IgG2a, anti-HLA35), and IB4 [IgG2a and F(ab′)2, anti-CD3836] have been described. OKT10 (IgG1 anti-CD38) and M300 (IgG1 myeloma protein, MOPC 300) were from the American Type Culture Collection (Manassas, VA). Actinomycin D was from Sigma Chemical Co (St Louis, MO).

Effector and target cells.

Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats from normal National Institutes of Health Blood Bank (Bethesda, MD) donors by Ficoll-Hypaque density gradient separation. Peripheral blood lymphocytes (PBLs) were prepared from PBMCs by monocyte depletion using plastic adherence, followed in some experiments by nylon wool adsorption.15 PBLs were activated for 6 days (unless stated otherwise) in culture medium (RPMI 1640 plus 10% fetal calf serum [FCS], glutamine, penicillin, and streptomycin) containing 200 to 400 Cetus Units/mL recombinant human interleukin-2 (rhIL-2; Cetus-Chiron, Emeryville, CA) and, in some experiments, 5% Lymphocult-T (conditioned medium from phytohemagglutinin [PHA]-activated PBMCs; Biotest Diagnostics, Denville, NJ). This procedure induces cytotoxic activity in NK and CD56+ T cells but does not activate the great majority of T cells, which lack CD56.37 NK cells were purified from unactivated or activated PBLs by negative selection using a Vario MACS system with an NK isolation kit (Miltenyi Biotec, Auburn, CA) and were always greater than 95% CD16+ and less than 1% CD3+. Cytotoxic T lymphocytes (CTLs) were obtained from high buoyant density PBLs38 that had been activated for 4 days with culture medium containing 200 to 400 Cetus Units/mL rhIL-2 and 5% Lymphocult-T and then negatively selected for CD56 using the Vario MACS system. P815 (mouse FcγR+ mastocytoma) target cells (American Type Culture Collection) were labeled with 51Cr as described.39 

Cytotoxicity assay.

Effector cells were incubated for 20 to 30 minutes at room temperature with or without MoAb (2.5 to 10 μg/mL) and diluted serially. Ten thousand 51Cr-labeled P815 target cells in 100 μL culture medium were then added to 100 μL of diluted effector cells, and cytotoxicity was measured in triplicate samples using a 4-hour51Cr-release assay.39 The percentage of specific lysis was calculated as follows: 100 × (CPMexperimental − CPMspontaneous)/(CPMmaximum − CPMspontaneous). Spontaneous release was 10% or less of the maximum in all experiments reported.

Surface expression.

Cells were incubated on ice for 30 minutes with either a fluorescein isothiocyanate (FITC)- or PE-conjugated MoAb, followed by a second incubation with an MoAb conjugated with the other fluorophore. They were washed twice and analyzed with a FACScan flow cytometer (Becton Dickinson Immunocytometry, San Jose, CA). Propidium iodide staining and forward and side light scatter were used to gate on viable cells, and a total of 5,000 to 10,000 cells were analyzed per measurement.

Effector-target conjugates.

Effector-target conjugates were detected by flow cytometry using a modification of a previously published procedure.40Activated NK cells were suspended in 5 mL phosphate-buffered saline (PBS) at a concentration of 2 × 106 cells/mL and 50 μL of 1 mmol/L FITC (Sigma) in ethanol was added. The cells were incubated for 5 minutes at 37°C, washed, centrifuged, and incubated on ice for 30 minutes with or without 2.5 μg of MoAb in a volume of 0.1 mL. After washing, Ficoll-Hypaque–fractionated P815 cells in a total volume of 0.1 mL RPMI 1640 were added at a target:effector ratio of 1.5:1. The cells were pelletted, incubated at room temperature for 1 hour, and gently resuspended in 0.5 mL PBS. NK cells could be distinguished from the P815 cells by flow cytometry on the basis of their lower side light scatter. Conjugates were calculated as the percentage of FITC+ cells having the same or higher side light scatter as the P815 cells. At least 10,000 FITC+ (NK) cells were analyzed, yielding 1,500 as the minimum number of conjugates detected in any experiment.

N-α-benzyloxycarbonyl-L-lysine thiobenzyl ester (BLT) thioesterase assay.

Serine esterase release from activated, purified NK cells was measured using a modification of a previously described method.41Briefly, 96-well Immulon microtiter immunoassay plates (Dynatech Laboratories, Chantilly, VA) were incubated overnight with 50 μL/well of 15 μg/mL MoAb in borate-buffered saline, pH 8.5. After 3 washes with PBS, 1 to 4 × 105 NK cells in 200 μL RPMI 1640 without phenol red and without serum but containing 400 U/mL IL-2 were added to each well. Plates were centrifuged for 5 minutes at 300g and incubated for 3 hours at 37°C in 5% CO2. After incubation, 50-μL aliquots of supernatants were transferred to a flat-bottom microtiter plate and 50 μL of 1 mmol/L 5′,5′-Dithio-bis-(2-nitrobenzoic acid) (DTNB; Sigma) in Hanks’ balanced salt solution (HBSS) was added to each well. Immediately after the addition of DTNB, plates were read at 414 nm using a Titertech (Huntsville, AL) Multiskan enzyme-linked immunosorbent assay (ELISA) reader to obtain blank values. One hundred microliters of 1 mmol/L BLT (Calbiochem, San Diego, CA) in HBSS was added to each well, and the plates were incubated at room temperature until a visible yellow color developed. The plates were again read in the ELISA reader, and blank values were subtracted.

Cytokine release.

Immulon 96-well microtiter immunoassay plates were incubated overnight with 50 μL/well of 25 μg/mL MoAb in borate-buffered saline, pH 8.5. After 3 washes with PBS, 3 × 105 IL-2–activated, purified NK cells in 200 μL complete medium were added to each well. After 20 hours of incubation at 37°C, cell-free supernatants were harvested and either tested immediately or stored at −20°C. Tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) levels were quantitated with Biosource International (Camarillo, CA) ELISA kits, following the manufacturer’s instructions. Limits of detection were 1 pg/mL for TNF-α and 4 pg/mL for IFN-γ.

Cytoplasmic Ca2+.

Cytoplasmic Ca2+ was measured by using the Fluo-3/AM fluorescent calcium marker, as described.42 Briefly, purified, IL-2–activated NK cells were washed with HBSS and loaded for 30 minutes at room temperature with 4 μmol/L Fluo-3/AM (Molecular Probes, Eugene, OR) in the presence of 0.06% Pluronic F-127 (Molecular Probes). Cells were diluted 5-fold in HBSS containing 1% FCS, incubated for 30 minutes at room temperature, washed 3 times, and kept at 4°C in HEPES-buffered saline (137 mmol/L NaCl, 5 mmol/L KCl, 1 mmol/L Na2HPO4, 5 mmol/L glucose, 1 mmol/L CaCl2, 0.5 mmol/L MgCl2, 1 mg/mL bovine serum albumin [BSA], and 10 mmol/L HEPES, pH 7.4). Five minutes before fluorescence-activated cell sorting (FACS) analysis, the Fluo-3–labeled cells were warmed to 37°C. They were then stimulated with 10 μg/mL of IB4 F(ab′)2, W6/32, or 3G8 MoAb, followed by the addition of 10 μg/mL of rabbit F(ab′)2 antimouse IgG (Southern Biotechnology, Birmingham, AL). Proper loading was checked by treating cells with 2 μg/mL of ionomycin.

CD38 is a cytotoxic triggering molecule in activated NK cells.

Although CD38 transduces a variety of signals in B-cell, T-cell, and granulocytic cell lines26-29 and induces a cytotoxic response in an MHC-unrestricted T-cell line,30 it is not known whether it has the capacity to trigger cytolysis in isolated subsets of PBLs. Therefore, PBLs from normal donors were incubated in reverse ADCC10 experiments with FcγR+ P815 target cells in the presence of either anti-CD38 MoAb or MoAbs against CD3 and CD16, known cytotoxic triggers in CTLs and NK cells, respectively. In these experiments, IgG MoAbs redirect lysis by simultaneously binding to FcγR on the target cells and to triggering molecules on the effector cells. P815 cells are of mouse origin and are not specifically recognized by antihuman CD38 or other mouse antihuman MoAbs used in this study. Figure 1A shows that IL-2–activated PBLs do in fact contain cells that mediate CD38-directed cytolysis. Purified NK cells and CTLs were then used to determine which types of cells mediate this activity. The purified NK cell preparation (Fig 1B) mediated moderate amounts of lysis of P815 cells, a relatively NK-resistant target, in the absence of MoAb. Lysis was not affected by anti-CD3 MoAb, indicating that levels of CTL contamination were negligible, but was markedly enhanced by the anti-CD38 and anti-CD16 MoAbs. By contrast, conventional CTL, depleted of NK cells and a small subset of T cells by CD56 negative selection, exhibited potent CTL activity, but failed to mediate CD38- or CD16-directed lysis. Removal of the Fc portion of IB4, the anti-CD38 MoAb used above, abrogated its capacity to mediated reverse ADCC, as expected, and OKT10, a less agonistic anti-CD38 MoAb than IB4,43 consistently mediated lysis at a lower level than IB4 (Fig 1D). FACS analysis (Fig 2) showed that all NK (CD16+) cells and the great majority of CTL expressed CD38. Thus, the inability of the anti-CD38 MoAb to trigger lysis by CTLs was not due to the lack of expression of CD38 on these cells. We conclude that CD38 is a cytotoxic trigger on activated NK cells but not on conventional CTLs.

Fig. 1.

CD38 is a cytotoxic triggering molecule for activated NK cells but not CTL. IL-2–activated PBLs (A), purified IL-2–activated NK cells (B), or CD56-depleted CTL (C) from separate donors were tested in reverse ADCC assays using anti-CD38 (IB4), anti-CD3 (OKT3), or anti-CD16 (3G8) MoAbs to redirect the lysis of P815 target cells. Effector:target (E:T) ratios are indicated in the legends. In (D), the indicated concentrations of intact IB4, IB4 F(ab′)2, intact OKT10 (a less agonistic anti-CD38 MoAb), and M300 (nonspecific IgG control) were used with PBLs at an E:T ratio of 15:1 to redirect lysis. All effector cells were preactivated as described in Materials and Methods. *P < .05, **P < .01 when compared with the no antibody control (A, B, and C) or the M300 control (D) at the same E:T ratio.

Fig. 1.

CD38 is a cytotoxic triggering molecule for activated NK cells but not CTL. IL-2–activated PBLs (A), purified IL-2–activated NK cells (B), or CD56-depleted CTL (C) from separate donors were tested in reverse ADCC assays using anti-CD38 (IB4), anti-CD3 (OKT3), or anti-CD16 (3G8) MoAbs to redirect the lysis of P815 target cells. Effector:target (E:T) ratios are indicated in the legends. In (D), the indicated concentrations of intact IB4, IB4 F(ab′)2, intact OKT10 (a less agonistic anti-CD38 MoAb), and M300 (nonspecific IgG control) were used with PBLs at an E:T ratio of 15:1 to redirect lysis. All effector cells were preactivated as described in Materials and Methods. *P < .05, **P < .01 when compared with the no antibody control (A, B, and C) or the M300 control (D) at the same E:T ratio.

Close modal
Fig. 2.

Expression of CD38 on NK cells and CTLs. Contour diagrams of PBL incubated for 3 days in (A) medium alone, (B) medium containing IL-2, and (C) medium containing IL-2 plus 10 ng/mL actinomycin D. (D) Single-parameter histogram showing CD38 expression on CTLs. In (A) through (C), the NK (CD16+) cells were 95%, 93%, and 99% CD38+, respectively, and the mean CD38 fluorescence intensities on the CD16+CD38+ cells were 147, 134, and 232. In (D), cells were 90% positive for CD3 (not shown) and 80% positive for CD38.

Fig. 2.

Expression of CD38 on NK cells and CTLs. Contour diagrams of PBL incubated for 3 days in (A) medium alone, (B) medium containing IL-2, and (C) medium containing IL-2 plus 10 ng/mL actinomycin D. (D) Single-parameter histogram showing CD38 expression on CTLs. In (A) through (C), the NK (CD16+) cells were 95%, 93%, and 99% CD38+, respectively, and the mean CD38 fluorescence intensities on the CD16+CD38+ cells were 147, 134, and 232. In (D), cells were 90% positive for CD3 (not shown) and 80% positive for CD38.

Close modal
Comparison of triggering functions of NK surface molecules.

Not all MoAbs against NK surface molecules consistently induced lytic responses. Table 1 shows that activated PBLs from most donors mediate CD38- and CD16-dependent lysis of P815 target cells at levels significantly above the antibody-independent background. By contrast, anti-MHC I and anti-CD11a MoAbs induced positive responses in only 18% and 0% of donors, respectively, although these same MoAbs bound to essentially all NK cells by FACS analysis (data not shown). Moreover, both triggering and nontriggering MoAbs were fully capable of inducing NK cell-target cell conjugate formation (Fig 3), indicating that conjugate formation, per se, is not a lytic signal in NK cells.

Table 1.

Percentage of Donors Mediating Directed Lysis of P815 Target Cells

MoAb Specificity % Active Donors*N
CD38  64 34  
CD16  85  27  
MHC I  18  11  
CD11a  0   5 
MoAb Specificity % Active Donors*N
CD38  64 34  
CD16  85  27  
MHC I  18  11  
CD11a  0   5 
*

Percentages of donors in which the indicated MoAb increased lysis more than 1.5-fold over natural cytotoxicity at at least 2 different E:T ratios.

Number of donors tested. IL-2–activated PBL were used as effectors.

Fig. 3.

Conjugates between P815 and NK cells. Purified FITC-labeled activated NK cells were coated with MoAb of the indicated specificity, washed, and mixed with P815 cells at a ratio of 1 NK cell to 1.5 P815. The cells were pelletted, incubated for 1 hour at room temperature, resuspended, and analyzed for light scatter and green fluorescence. Conjugates were detected as FITC+ particles with side scatter greater or equal to that of P815 cells.

Fig. 3.

Conjugates between P815 and NK cells. Purified FITC-labeled activated NK cells were coated with MoAb of the indicated specificity, washed, and mixed with P815 cells at a ratio of 1 NK cell to 1.5 P815. The cells were pelletted, incubated for 1 hour at room temperature, resuspended, and analyzed for light scatter and green fluorescence. Conjugates were detected as FITC+ particles with side scatter greater or equal to that of P815 cells.

Close modal
Induction of CD38-dependent lysis.

Unstimulated NK cells mediated little if any CD38-dependent lysis, but culture with IL-2 induced both CD38-dependent lysis and Ab-independent cytotoxicity (Fig 4). By contrast, unstimulated NK cells did mediate CD16-directed lysis, indicating that they were competent killer cells before activation (Fig 4). CD38 expression was similar on both activated and unstimulated cells (Fig 2B and A), indicating that the acquisition of CD38 triggering function was not due to enhanced CD38 surface expression. To determine whether de novo gene expression was required for the induction of CD38-directed lysis, PBLs were activated in the presence of varying concentrations of the transcription inhibitor, actinomycin D. As shown in Fig 5, actinomycin D, even at 10 ng/mL, had little effect on the acquisition or maintenance of lysis mediated by CD16, indicating that it did not impair the cytolytic function of NK cells in general. By contrast, actinomycin D strongly inhibited the induction of CD38-dependent lysis and Ab-independent cytotoxicity (Fig5), but had a negligible effect on CD38 expression (Fig 2C). These data suggest that IL-2 induced the expression of at least 1 protein, distinct from CD38 itself, that was required for CD38 lytic function.

Fig. 4.

IL-2 activation induces CD38 triggering function. Cells from 2 normal donors were cultured with 200 U/mL IL-2 for the indicated times and tested for the ability to lyse P815 target cells in the presence of medium alone (no Ab), anti-CD38, or anti-CD16 MoAbs. Lytic units were calculated from the E:T ratio giving 25% (donor 1) or 20% (donor 2) lysis (lytic units = 100/E:T). Asterisks indicate that lysis was less than 25% and 20% for donors 1 and 2, respectively, at all E:T. This experiment has been repeated 4 times with similar results. CD38-directed lysis appeared in different donors as early as 16 hours and as late as 4 days.

Fig. 4.

IL-2 activation induces CD38 triggering function. Cells from 2 normal donors were cultured with 200 U/mL IL-2 for the indicated times and tested for the ability to lyse P815 target cells in the presence of medium alone (no Ab), anti-CD38, or anti-CD16 MoAbs. Lytic units were calculated from the E:T ratio giving 25% (donor 1) or 20% (donor 2) lysis (lytic units = 100/E:T). Asterisks indicate that lysis was less than 25% and 20% for donors 1 and 2, respectively, at all E:T. This experiment has been repeated 4 times with similar results. CD38-directed lysis appeared in different donors as early as 16 hours and as late as 4 days.

Close modal
Fig. 5.

Gene transcription is required for the induction of natural cytotoxicity and CD38-dependent lysis. PBLs from 2 separate donors were activated for 3.5 days in medium containing 200 U/mL IL-2 and the indicated concentrations of actinomycin D. Cells were then tested for the ability to mediate natural cytotoxicity (No Ab) or cytotoxicity directed by anti-CD38 or anti-CD16 MoAbs.

Fig. 5.

Gene transcription is required for the induction of natural cytotoxicity and CD38-dependent lysis. PBLs from 2 separate donors were activated for 3.5 days in medium containing 200 U/mL IL-2 and the indicated concentrations of actinomycin D. Cells were then tested for the ability to mediate natural cytotoxicity (No Ab) or cytotoxicity directed by anti-CD38 or anti-CD16 MoAbs.

Close modal
CD38 cross-linking triggers degranulation and cytokine release.

Cell-mediated cytolysis requires the formation of multicellular conjugates between effector and target cells and could involve ligation of several different receptors on the killer cells. To determine whether the cross-linking of CD38 alone could trigger functional responses, activated, purified NK cells were incubated with immobilized MoAbs, and the supernatants were tested for esterase or cytokine release (Fig 6). Immobilized anti-CD38 F(ab′)2 promoted esterase, IFN-γ, and TNF-α release at levels that were clearly above the medium control, but that were usually lower than those induced by anti-CD16 MoAb. By contrast, MoAbs against CD56 and MHC I, 2 molecules expressed on NK cell surfaces, failed to trigger cytokine or esterase release. Esterase release results from the exocytosis of stored cytolytic substances such as perforin and granzymes, whereas cytokine release requires de novo protein synthesis. Thus, the cross-linking of CD38 with immobilized F(ab′)2 triggered 2 fundamentally different processes used in NK effector responses.

Fig. 6.

Triggered degranulation and cytokine release. Purified IL-2–activated NK cells were incubated in microtiter wells coated with no Ab, anti-CD16 MoAb, anti-CD38 F(ab′)2, anti-CD56 MoAb, or anti–MHC-1 MoAb for 3 (esterase release) or 20 (cytokine release) hours. Supernatants were removed and tested for BLT-esterase (upper panel), TNF- (middle panel), or IFN-γ (lower panel). Cells from different donors were used for measuring esterase and cytokine release. *P < .05. **P < .01 as compared with the no antibody control.

Fig. 6.

Triggered degranulation and cytokine release. Purified IL-2–activated NK cells were incubated in microtiter wells coated with no Ab, anti-CD16 MoAb, anti-CD38 F(ab′)2, anti-CD56 MoAb, or anti–MHC-1 MoAb for 3 (esterase release) or 20 (cytokine release) hours. Supernatants were removed and tested for BLT-esterase (upper panel), TNF- (middle panel), or IFN-γ (lower panel). Cells from different donors were used for measuring esterase and cytokine release. *P < .05. **P < .01 as compared with the no antibody control.

Close modal
Lack of CD38-induced Ca2+ mobilization in NK cells.

Cross-linking of CD38 induces an increase in intracellular Ca2+ in Jurkat,27 but not in immature B cells28 or MHC-nonrestricted CTLs.30 We therefore asked whether CD38 cross-linking would trigger Ca2+ mobilization in NK cells. Fluo-3–loaded NK cells, isolated from PBLs that mediated high levels of CD38-dependent lysis (Fig 1A) were treated with either anti-CD38 F(ab′)2, anti-CD16 MoAb (positive control), or anti-MHC I MoAb (negative control), followed by further cross-linking (right arrow) with antimouse Ig. As seen in Fig 7, only the anti-CD16 MoAb induced an increase in intracellular Ca2+. Similar results were obtained using biotin-MoAbs and streptavidin as a cross-linker (data not shown). We conclude that CD38 cross-linking in NK cells does not trigger Ca2+ mobilization and that the CD38 and CD16 signaling pathways differ in this regard.

Fig. 7.

Cross-linking of CD16 but not CD38 induces an increase in intracellular Ca2+. Purified, IL-2–activated NK cells were loaded with Fluo-3, warmed to 37°C, and, at the time indicated by the left arrow, treated with anti-CD38 (IB4) F(ab′)2 (•) anti–MHC-1 (W6/32) MoAb (▿), or anti-CD16 (3G8) MoAb (▪). At the time indicated by the right arrow, antibodies were further cross-linked by the addition of rabbit F(ab′)2 antimouse IgG. Cytolysis mediated by PBLs from this donor is shown in Fig 1A. This experiment has been repeated 4 times, with similar results.

Fig. 7.

Cross-linking of CD16 but not CD38 induces an increase in intracellular Ca2+. Purified, IL-2–activated NK cells were loaded with Fluo-3, warmed to 37°C, and, at the time indicated by the left arrow, treated with anti-CD38 (IB4) F(ab′)2 (•) anti–MHC-1 (W6/32) MoAb (▿), or anti-CD16 (3G8) MoAb (▪). At the time indicated by the right arrow, antibodies were further cross-linked by the addition of rabbit F(ab′)2 antimouse IgG. Cytolysis mediated by PBLs from this donor is shown in Fig 1A. This experiment has been repeated 4 times, with similar results.

Close modal

It is well known that NK cells lyse tumor and virally infected cells in the absence of Ab, but the receptors used in target cell recognition are poorly defined. In this report, we show that CD38 is a receptor that could potentially contribute to natural cytotoxicity mediated by IL-2–activated NK cells. The signaling capacity of CD38 was demonstrated by using an anti-CD38 MoAb to mimic its interaction with CD31, a ligand for CD38 that is present in especially high amounts on endothelial cells. The choice of target cell is particularly important in these studies. P815 was chosen not only because it expresses FcγR and is of mouse origin (and therefore does not interact with the mouse antihuman receptor antibodies used here), but also because it is relatively resistant to natural cytotoxicity. Natural cytotoxicity is the result of several positive signaling interactions being balanced by negative signals. An NK target such as K562 that expresses low levels of MHC I molecules is lysed so efficiently that no further increases can be seen on the addition of antibody. On the other hand, very high engagement of inhibitory molecules could totally block redirected lysis (eg, see Meyaard et al5). P815 falls between these 2 extremes. In fact, we did attempt to use an endothelial cell line that expresses high levels of CD31 as a target cell (data not shown). Natural cytotoxicity of this target was quite high, and anti-CD38 or anti-CD31 were unable to significantly inhibit lysis, presumably because other triggering molecules contributed to cytotoxic signaling.

The killing capacity of CD38 appeared to be mediated primarily by activated NK cells. Conventional CTLs and unactivated NK cells expressed CD38 on their surfaces and mediated lysis through CD3 and CD16, respectively, but failed to kill through CD38. Because of our separation procedures, we could not establish whether the CD56+ T cells were also triggered by CD38 ligation. This NK-like subset of T cells comprises 2% to 3% of total PBLs and is the primary mediator of CD3 directed lysis in IL-2–activated PBLs. By contrast, the more abundant conventional CTL are CD3+, CD56 and require T-cell receptor (TCR) cross-linking in addition to cytokine for activation.9 Recent studies by Cesano et al30 provide evidence on the role of CD38 in the activation of CD56+, CD3+ T cells. In their experiments, the IB4 anti-CD38 MoAb triggered low levels of cytolysis by the CD56+, CD3+ TALL line and no lysis by unfractionated LAK cells that were 90% T cells. In addition, anti-CD38 failed to induce an increase in intracellular Ca2+ levels in both cell types. However, IB4 did induce low, but significant levels of esterase release by both cell types, and gave robust cytokine responses. Thus, to the extent that the TALL cells and unfractionated LAK represent CD56+ T cells, it appears that this subset of cells behaves similar to NK cells in response to anti-CD38, except that they are less cytotoxic.

The acquisition of CD38 triggering capacity by NK cells during activation with IL-2 was blocked by actinomycin D, an inhibitor of transcription, suggesting that CD38 lytic function depends on the de novo synthesis of 1 or more proteins that are essential components of the lytic pathway. Because actinomycin D had no significant effect on CD38 expression, the newly synthesized proteins must have acted downstream of CD38. There are 2 known pathways by which lymphocytes lyse target cells in 4 hours (the time used in the current study): granule exocytosis and cross-linking of death receptors such as Fas on target cells.44 We demonstrate here that both anti-CD38 and anti-CD16 MoAbs induce degranulation (BLT-esterase release) of NK cells; in addition, the target cells used in this study did not express Fas (CD95) either by functional or FACS analysis (data not shown). Thus, CD16 and CD38 most likely killed through the granule exocytosis pathway. Because actinomycin D had little effect on CD16-mediated lysis on either activated or fresh NK cells, it is unlikely that the putative, IL-2–induced proteins were involved in the degranulation process itself. Thus, it is likely that IL-2 induced the synthesis of proteins that act between CD38 and degranulation. Previously, we demonstrated that CD44, like CD38, acquired cytotoxic triggering capacity during NK cell activation and that this gain in function was actinomycin inhibitable but not dependent on receptor expression.45 Thus, the de novo synthesis of proteins that link adhesion molecules to the killing machinery may be an important component of NK cell-mediated lysis in general.

In the Jurkat T-cell line, CD38 ligation induces the tyrosine phosphorylation of several proteins used in TCR signaling, including ζ, ZAP-70, and PLC-γ1, as well as proteins in the Raf-1/MAP kinase pathway.26 Cross-linking of CD38 on Jurkat cells also induces an increase in intracellular Ca2+ and apoptosis, both of which require an intact TCR.27 CD16 ligation on NK cells initiates a signaling pathway that mirrors that of the TCR in that it induces phosphorylation of ζ and homologous γ subunits, phosphorylation of ZAP-70 and syk,1 and an increase in intracellular Ca2+.46 In addition, it has been reported that CD16 associates with CD38 on NK cell surfaces.36 Thus, it seemed possible that the CD38 and CD16 triggering pathways on NK cells might merge either at the level of CD16 itself or downstream of CD16. However, the fact that CD38 cross-linking does not induce an increase in intracellular Ca2+, whereas CD16 ligation does, suggests that the 2 triggering molecules use different signaling pathways.

The number of adhesion molecules that can serve as cytotoxic triggers on NK cells, which now include CD2, CD38, CD44, and CD69, continues to increase, suggesting that the process of natural cytotoxicity may not be triggered by specialized NK receptors, but may instead reflect the level of expression of downstream proteins that confer triggering capacity on commonly expressed receptors. This mechanism of triggering might be fundamental to the cellular arm of innate immunity, but would be avoided by cellular mediators of acquired immunity, in which it would override a highly specific interaction with one that was less specific. Thus, it is not surprising that CD38 and CD44 trigger lysis on NK cells, but fail to do so when expressed on bulk CTLs generated from PBLs15 (although some CTL clones mediate CD44-directed lysis47,48). It has been shown that CD44 is a cytotoxic trigger in neutrophils,49 but it remains to be established how extensively cellular mediators of innate immunity use adhesion molecules to initiate cytolytic responses.

F.M. was supported by AIRC (Milan, Italy), TELETHON (Rome, Italy), and by the AIDS and TB Projects (Higher Institute of Medicine, Rome, Italy).

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

1
Leibson
 
PJ
Signal transduction during natural killer cell activation: Inside the mind of a killer.
Immunity
6
1997
655
2
Lanier
 
LL
Natural killer cells: From no receptors to too many.
Immunity
6
1997
371
3
Lanier
 
LL
NK cell receptors.
Annu Rev Immunol
16
1998
359
4
Yokoyama
 
WM
Natural killer cell receptors.
Curr Opin Immunol
10
1998
298
5
Meyaard
 
L
Adema
 
GJ
Chang
 
C
Woollatt
 
E
Sutherland
 
GR
Lanier
 
LL
Phillips
 
JH
LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes.
Immunity
7
1997
283
6
Daeron
 
M
Fc receptor biology.
Annu Rev Immunol
15
1997
203
7
Lanier
 
LL
Corliss
 
BC
Wu
 
J
Leong
 
C
Phillips
 
JH
Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells.
Nature
391
1998
703
8
Mason
 
LH
Willette-Brown
 
J
Anderson
 
SK
Gosselin
 
P
Shores
 
EW
Love
 
PE
Ortaldo
 
JR
McVicar
 
DW
Characterization of an associated 16-kDa tyrosine phosphoprotein required for Ly-49D signal transduction.
J Immunol
160
1998
4148
9
Segal
 
DM
Bakacs
 
T
Jost
 
CR
Kurucz
 
I
Sconocchia
 
G
Titus
 
JA
T cell-targeted cytotoxicity
Bispecific Antibodies.
Fanger
 
MW
1995
27
R.G. Landes
Austin, TX
10
Segal
 
DM
Vance
 
BA
Sconocchia
 
G
Bispecific antibodies
Antibodies in Diagnosis and Therapy.
Matzku
 
S
Stahel
 
RA
1999
49
Mechanisms and Clinical Data. Amsterdam, The Netherlands, Harwood Academic
Technologies
11
Siliciano
 
RF
Pratt
 
JC
Schmidt
 
RE
Ritz
 
J
Reinherz
 
EL
Activation of cytotoxic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein.
Nature
317
1985
428
12
Schmidt
 
RE
Michon
 
JM
Woronicz
 
J
Schlossman
 
SF
Reinherz
 
EL
Ritz
 
J
Enhancement of natural killer function through activation of the T11 E rosette receptor.
J Clin Invest
79
1987
305
13
Bolhuis
 
RLH
Roozemond
 
RC
van de Griend
 
RJ
Induction and blocking of cytolysis in CD2+, CD3− NK and CD2+, CD3+ cytotoxic lymphocytes via CD2 50 KD sheep erythrocyte receptor.
J Immunol
136
1986
3939
14
Galandrini
 
R
De Maria
 
R
Piccoli
 
M
Frati
 
L
Santoni
 
A
CD44 triggering enhances human NK cell cytotoxic functions.
J Immunol
153
1994
4399
15
Sconocchia
 
G
Titus
 
JA
Segal
 
DM
CD44 is a cytotoxic triggering molecule in human peripheral blood NK cells.
J Immunol
153
1994
5473
16
Tan
 
PH
Liu
 
YF
Santos
 
EB
Sandmaier
 
BM
Mechanisms of enhancement of natural killer activity by an antibody to CD44: Increase conjugate formation and release of tumor necrosis factor α.
Cell Immunol
164
1995
255
17
Moretta
 
A
Poggi
 
A
Pende
 
D
Tripodi
 
G
Orengo
 
AM
Pella
 
N
Augugliaro
 
R
Bottino
 
C
Ciccone
 
E
Moretta
 
L
CD69-mediated pathway of lymphocyte activation: Anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor α/β.
J Exp Med
174
1991
1393
18
Giorda
 
R
Rudert
 
WA
Vavassori
 
C
Chambers
 
WH
Hiserodt
 
JC
Trucco
 
M
NKR-P1, a signal transduction molecule on natural killer cells.
Science
249
1990
1298
19
Martin-Fontecha
 
A
Assarsson
 
E
Carbone
 
E
Karre
 
K
Ljunggren
 
HG
Triggering of murine NK cells by CD40 and CD86 (B7-2).
J Immunol
162
1999
5910
20
Frey
 
JL
Bino
 
T
Kantor
 
RR
Segal
 
DM
Giardina
 
SL
Roder
 
J
Anderson
 
S
Ortaldo
 
JR
Mechanism of target cell recognition by natural killer cells: Characterization of a novel triggering molecule restricted to CD3-large granular lymphocytes.
J Exp Med
174
1991
1527
21
Mehta
 
K
Shahid
 
U
Malavasi
 
F
Human CD38, a cell-surface protein with multiple functions.
FASEB J
10
1996
1408
22
Deaglio
 
S
Morra
 
M
Horenstein
 
A
Mallone
 
R
Ausiello
 
CM
Prager
 
E
Garbarino
 
G
Dianzani
 
U
Stockinger
 
H
Malavasi
 
F
Human CD38 (ADP-ribosyl cyclase) is a ligand of CD31, an Ig superfamily member.
J Immunol
160
1998
395
23
Shubinsky
 
G
Schlesinger
 
M
The CD38 lymphocyte differentiation marker: New insight into its ectoenzymatic activity and its role as a signal transducer.
Immunity
7
1997
315
24
Blom
 
B
Res
 
P
Noteboom
 
E
Weijer
 
K
Spits
 
H
Prethymic CD34+ progenitors capable of developing into T cells are not committed to the T cell lineage.
J Immunol
158
1997
3571
25
Jaleco
 
AC
Blom
 
B
Res
 
P
Weijer
 
K
Lanier
 
LL
Phillips
 
JH
Spits
 
H
Fetal liver contains committed NK progenitors, but is not a site for development of CD34+ cells into T cells.
J Immunol
159
1997
694
26
Zubiaur
 
M
Izquierdo
 
M
Terhorst
 
C
Malavasi
 
F
Sancho
 
J
CD38 ligation results in activation of the Raf-1/mitogen-activated protein kinase and the CD3-zeta/zeta-associated protein-70 signaling pathways in Jurkat T lymphocytes.
J Immunol
159
1997
193
27
Morra
 
M
Zubiaur
 
M
Terhorst
 
C
Sancho
 
J
Malavasi
 
F
CD38 is functionally dependent on TCR/CD3 complex in human T cells.
FASEB J
12
1998
581
28
Silvennoinen
 
O
Nishigaki
 
H
Kitanaka
 
A
Kumagai
 
M
Ito
 
C
Malavasi
 
F
Lin
 
Q
Conley
 
ME
Campana
 
D
CD38 signal transduction in human B cell precursors. Rapid induction of tyrosine phosphorylation, activation of syk tyrosine kinase, and phosphorylation of phospholipase C-gamma and phosphatidylinositol 3-kinase.
J Immunol
156
1996
100
29
Kontani
 
K
Kukimoto
 
I
Nishina
 
H
Hoshino
 
S
Hazeki
 
O
Kanaho
 
Y
Katada
 
T
Tyrosine phosphorylation of the c-cbl proto-oncogene product mediated by cell surface antigen CD38 in HL-60 cells.
J Biol Chem
271
1996
1534
30
Cesano
 
A
Visonneau
 
S
Deaglio
 
S
Malavasi
 
F
Santoli
 
D
Role of CD38 and its ligand in the regulation of MHC-nonrestricted cytotoxic T cells.
J Immunol
160
1998
1106
31
Lund
 
FE
Cockayne
 
DA
Randall
 
TD
Solvason
 
N
Schuber
 
F
Howard
 
MC
CD38: A new paradigm in lymphocyte activation and signal transduction.
Immunol Rev
161
1998
79
32
Peola
 
S
Borrione
 
P
Matera
 
L
Malavasi
 
F
Pileri
 
A
Massaia
 
M
Selective induction of CD73 expression in human lymphocytes by CD38 ligation: A novel pathway linking signal transducers with ecto-enzyme activities.
J Immunol
157
1996
4354
33
Fleit
 
HB
Wright
 
SD
Unkeless
 
JC
Human neutrophil Fc gamma receptor distribution and structure.
Proc Natl Acad Sci USA
79
1982
3275
34
Kung
 
P
Goldstein
 
G
Reinherz
 
EL
Schlossman
 
SF
Monoclonal antibodies defining distinctive human T cell surface antigens.
Science
206
1979
347
35
Barnstable
 
CJ
Bodmer
 
WF
Brown
 
G
Galfre
 
G
Milstein
 
C
Williams
 
AF
Ziegler
 
A
Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens–New tools for genetic analysis.
Cell
14
1978
9
36
Funaro
 
A
De Monte
 
LB
Dianzani
 
U
Forni
 
M
Malavasi
 
F
Human CD38 is associated to distinct molecules which mediate transmembrane signaling in different lineages.
Eur J Immunol
23
1993
2407
37
Garrido
 
MA
Perez
 
P
Titus
 
JA
Valdayo
 
MJ
Winkler
 
DA
Barbieri
 
SA
Wunderlich
 
JR
Segal
 
DM
Targeted cytotoxic cells in human peripheral blood lymphocytes.
J Immunol
144
1990
2891
38
Phillips
 
JH
Warner
 
NL
Lanier
 
LL
Correlation of biophysical properties and cell surface antigenic profile of Percoll gradient-separated human natural killer cells.
Nat Immun Cell Growth Regul
3
1983
73
39
Wunderlich
 
JR
Shearer
 
GM
Induction and measurement of cytotoxic T lymphocyte activity, Unit 3.11
Current Protocols in Immunology, vol 1.
Coligan
 
JE
Kruisbeek
 
AM
Margulies
 
DH
Shevach
 
EM
Strober
 
W
1991
3.11.1
Wiley
New York, NY
40
Segal
 
DM
Measurement of intercellular conjugates by flow cytometry
Current Protocols in Immunology.
Coligan
 
JE
Kruisbeek
 
AM
Margulies
 
DH
Shevach
 
EM
Strober
 
W
1997
5.6.1
Wiley
New York, NY
41
Taffs
 
R
Sitkovsky
 
MV
Granule enzyme exocytosis assay for cytotoxic T lymphocyte activation
Current Protocols in Immunology.
Coligan
 
JE
Kruisbeek
 
AM
Margulies
 
DH
Shevach
 
EM
Strober
 
W
1991
3.16.1
Wiley
New York, NY
42
Vandenberghe
 
PA
Ceuppens
 
JL
Flow cytometric measurement of cytoplasmic free calcium in human peripheral blood T lymphocytes with fluo-3, a new fluorescent calcium indicator.
J Immunol Methods
127
1990
197
43
Zupo
 
S
Rugari
 
E
Dono
 
M
Taborelli
 
G
Malavasi
 
F
Ferrarini
 
M
CD38 signaling by agonistic monoclonal antibody prevents apoptosis of human germinal center B cells.
Eur J Immunol
24
1994
1218
44
Henkart
 
PA
Lymphocyte-mediated cytotoxicity: Two pathways and multiple effector molecules.
Immunity
1
1994
343
45
Sconocchia
 
G
Titus
 
JA
Segal
 
DM
Signaling pathways regulating CD44-dependent cytolysis in NK cells.
Blood
90
1997
716
46
Cassatella
 
MA
Anegon
 
I
Cuturi
 
MC
Griskey
 
P
Trinchieri
 
G
Perussia
 
B
Fc gamma R(CD16) interaction with ligand induces Ca2+ mobilization and phosphoinositide turnover in human natural killer cells. Role of Ca2+ in Fc gamma R(CD16)-induced transcription and expression of lymphokine genes.
J Exp Med
169
1989
549
47
Seth
 
A
Gote
 
L
Nagarkatti
 
M
Nagarkatti
 
PS
T-cell-receptor-independent activation of cytolytic activity of cytotoxic T lymphocytes mediated through CD44 and gp90MEL-14.
Proc Natl Acad Sci USA
88
1991
7877
48
Galandrini
 
R
Albi
 
N
Tripodi
 
G
Zarcone
 
D
Terenzi
 
A
Moretta
 
A
Grossi
 
CE
Velardi
 
A
Antibodies to CD44 trigger effector functions of human T cell clones.
J Immunol
150
1993
4225
49
Pericle
 
F
Sconocchia
 
G
Titus
 
JA
Segal
 
DM
CD44 is a cytotoxic triggering molecule on human polymorphonuclear cells.
J Immunol
157
1996
4657

Author notes

Address reprint requests to David M. Segal, PhD, Bldg 10, Room 4B36, NIH, Bethesda, MD 20892-1360.

Sign in via your Institution